Aydın Çiltaş

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Surgical intervention may not always be required in gossypiboma with intraluminal migration

Ali Rıza Soylu, Kemal Dolay, Murat Kalaycı et al. · World Journal of Gastroenterology · 2007 · 36 citations · Full text

Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin

Aliye Soylu, Ali Tüzün İnce, Hakan Polat et al. · Annals of Clinical Microbiology and Antimicrobials · 2009 · 28 citations · Full text

Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Önder Tonyalı, Uğur Çoşkun, Sinemis Yuksel et al. · The Breast · 2015 · 25 citations

Breast Oncology, Medicine, Brain Metastasis +8

Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection

Mehmet Alı Nahıt Şendur, Umut Kefeli, Olçun Ümit Ünal et al. · Clinical Colorectal Cancer · 2016 · 23 citations

Prognostic Factors, Surgical Oncology, Gastrointestinal Oncology +8